MedTrace Logo

Long Acting Insulin Glargine Titration Web Tool (LTHome) vs Enhanced Usual Therapy of Glargine Titration

NCT02540486 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 139

Last updated 2015-09-04

No results posted yet for this study

Summary

Evaluating patients with type 2 diabetes either starting once daily basal insulin or requiring increased basal titrations in order to compare the LTHome web based tool with the usual standard of practice for insulin glargine dosing adjustment.

Conditions

Interventions

OTHER

Long-acting insulin glargine titration web tool (LTHome)

The LTHome study arm will receive insulin glargine titration instructions from the LTHome web-based tool

OTHER

Diabetes Education

Individual diabetes education, detailed instructions on the use of the blood glucose monitor and unlimited availability of blood glucose monitoring supplies.

Sponsors & Collaborators

  • Sanofi

    collaborator INDUSTRY

  • LMC Diabetes & Endocrinology Ltd.

    lead OTHER

Principal Investigators

  • Ronnie Aronson, MD · LMC Diabetes & Endocrinology Ltd.

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-12-31
Primary Completion
2015-03-31
Completion
2015-03-31

Countries

  • Canada

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02540486 on ClinicalTrials.gov